Treatment with oral ubrogepant (Ubrelvy) during the migraine prodrome led to more patients being able to function normally, a prespecified secondary endpoint analysis of the phase III PRODROME trial ...

Treating migraine before the pain starts: New research shows ubrogepant eases premonitory symptoms, offering hope for millions seeking earlier and more effective relief. Study: Ubrogepant for the ...

Ubrogepant, the newly approved calcitonin gene-related peptide antagonist, can relieve migraine symptoms within 2 hours after initial dose. Ubrogepant has been shown to relieve migraine pain and ...

A drug to treat migraine, ubrogepant, is also found to reduce common non-headache symptoms that occur in the hours preceding a migraine headache, according to the results of a large phase three ...

Ubrogepant is beneficial for the treatment of migraine when taken during the prodrome, according to a study published online Nov. 15 in The Lancet. David W. Dodick, M.D., from the Mayo Clinic in ...

The FAST study, officially titled “Evaluation of Function And Satisfaction of UbrogepanT-treated Migraine Patients in Canada,” looks at how well adults function and how satisfied they feel after using ...

New research shows that taking ubrogepant at the first signs of a migraine can prevent headache pain and keep your day on track. Effect of Ubrogepant on Patient-Reported Outcomes When Administered ...

Individuals administered ubrogepant for the acute treatment of migraine reported improvements in migraine-associated pain and functional disability, as well as general satisfaction with treatment.

Share on Pinterest Taken at onset, ubrogepant may stop migraine attacks in their tracks. Image credit: Guido Mieth/Getty Images. Migraine attacks are painful events that can cause many unpleasant ...

LOS ANGELES — Both primary efficacy endpoints were met in the phase 3 ACHIEVE I trial, a randomized controlled study comparing the novel oral calcitonin gene-related peptide (CGRP) receptor antagonist ...